Click Therapeutics raised Series D funding, then cut more than a quarter of its workforce shortly after. Fresh capital creates the cushion to make hard headcount calls without burning through the new money mid-restructuring.
For a digital therapeutics startup, this sequence is familiar. Digital therapeutics companies build software-based treatments, and their cost structure, heavy on clinical, regulatory, and development staff, can balloon fast. A late-stage financing round often precedes a workforce reset when the burn rate no longer fits the business model.
The digital therapeutics sector has been pruning. Others pivoted or quietly wound down. Click is still operating, but with a smaller team.
Series D capital isn’t cheap. Investors didn’t put that much in to maintain headcount. They funded the platform. What the deal actually buys depends on what survived the cuts.
If the layoffs hit operations and overhead, the core product is intact. If they cut into development, this round buys time.
The round closed. The team shrank. The capital has to count.
Diana Kowalski